Treating Cancer Dr Prinitha Pillay

Dr Prinitha Pillay Activist Oncologist Without Borders. Tweets dedicated to scientific advances, evidence and improved access to treatment.

[Treating Cancer Dr Prinitha Pillay @TreatingC]

Grateful to Get it magazine to recognise importance of #cancer Dr Prinitha Pillay Oncologist 🙏

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

My @ASTRO_org 2026 GU spring refresher extended "long-course" slide deck is available at
https://t.co/HND3LmzgZb

You can also watch the "short-course" 1.5 hour narrated version here:
https://t.co/GpDtfapF4K

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

2026 Genitourinary Oncology Spring Refresher - Dry Run

Updates in the management of cancers of the prostate, bladder, kidney, testes, from @NCCN @ASTRO_org @ESTRO_RT @Uroweb

#Radonc residents @ARRO_org, I hope it helps you ace the board exams!

https://t.co/5X8nP1NX0j

[Rashid K. Sayyid @RKSayyid]

#ASCOGU26

Real-world ADT CV outcomes (MarketScan; n=17,336) in prostate cancer

🔹2-pt MACE: 3.5/100 PY; 3-pt MACE: 4.0/100 PY
🔹GnRH agonists: 3.6 & 4.1/100 PY
🔹GnRH antagonists: 2.3 & 2.6/100 PY
🔹Relugolix lowest: 1.7 & 1.9/100 PY
🔹Patients w/ baseline CVD → much higher risk (~9.7 & 11.0/100 PY)

📌MACE low overall post-ADT; antagonists (esp relugolix) numerically safer → careful CV risk stratification remains key

@urotoday

[Shilpa Gupta @shilpaonc]

What a great Day 1 at #ASCOGU26! Meeting friends & colleagues & learning about latest data in #ProstateCancer

Key Takeaways
👉PEACE-3: ARPI + radium-223 improves OS in mCRPC
👉BRCAAway: Upfront PARPi + abiraterone > sequential Tx in BRCA mCRPC
👉 PSMAaddition: Early Lu-PSMA maintains QOL
👉ASCENDE-RT: Better control, ↑ GU toxicity

Patient selection matters!
@OncoAlert @oncodaily @Uromigos @DrYukselUrun

[Tuğba Başoğlu, MD @tugbawitter]

PEACE-2 Phase III takeaway #ASCOGU26 : escalation has limits.

In very high-risk localized prostate cancer, adding cabazitaxel to long-term ADT + radiotherapy:

❌ Did not improve cPFS (HR 1.11)
❌ No OS benefit
⚠️ Higher ≥G2 toxicity (65% vs 47%)
More treatment ≠ better outcomes.
Optimizing local-systemic balance remains key.
@ASCO @Larvol @OncoAlert @Uromigos

[Mustafa Özdoğan, MD @ozdogan_md]

20+ years in the making! #ASCOGU26 delivers a historic paradigm shift in Muscle-Invasive Bladder Cancer.

KEYNOTE-B15 (LBA630) demonstrates that perioperative EV + Pembrolizumab unequivocally outperforms the platinum chemo standard in cisplatin-eligible MIBC.

A new global standard of care is officially established.

#BladderCancer #MIBC #Oncology #UroOnc #MedTwitter #ASCO @ASCO

[Rashid K. Sayyid @RKSayyid]

#ASCOGU26

ARTO trial (Ph2, n=157; f/u: 53 mo): Abiraterone +/- SBRT in 1L oligometastatic CRPC

Benefit with SBRT:
🔷 bPFS: HR 0.49 (p<0.001)
🔷 rPFS: HR 0.48 (p<0.001)
🔷 OS: HR 0.55
🔷 PCSS: HR 0.37 (p=0.006)

📌63% relative reduction in prostate cancer–specific death with metastasis-directed SBRT.

@urotoday

[Mustafa Özdoğan, MD @ozdogan_md]

#ASCOGU26 — POSEIDON Study

Adding ADT to salvage radiotherapy after prostatectomy improves survival only when PSA > 0.5 ng/mL.

For early recurrence (PSA ≤ 0.5), RT alone appears sufficient.

Short-term ADT (4–6 months) is adequate.

#ASCO #ProstateCancer #RadiationOncology @L@Larvol

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

What is the ideal duration of hormone therapy for the treatment of prostate cancer?

https://t.co/E2LEjOAc0U

Video summary of https://t.co/9omNEdNL9v

[Brian Lawenda MD @BLawenda]

@UOzkerim https://t.co/ieGKZSgcJZ

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

My PSA is rising after prostate cancer surgery: what should I do?

A guide for patients to help conceptualize the framework for treatment decisions

#pcsm

https://t.co/5khf4TMrL5

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Lymph node stations of the thorax

Illustration based on @IASLC @UMichiganNews anatomic guides

[UroToday.com @urotoday]

Metastatic hormone-sensitive #ProstateCancer – So many randomized trials (nine), yet monotherapy treatment persists. Presented by @OncHahn @MDAndersonNews. #AUA25 written coverage by @RKSayyid @USC &gt; https://t.co/YUGFBH43UF @AmerUrological

[Jeff Ryckman @jryckman3]

#RadOnc Heme High-Yield Oral Boards: 2025 Update!

Some key slides highlighted below. Feedback or commentary is welcome.

Good luck everyone!

https://t.co/wqpGuC0VrI

[Stephanie Dudzinski MD, PhD @StephDudzinski]

1/ My first tweetorial debut on why 2024 was the year that solidified #radonc's seat at the #GIOnc multidisciplinary tumor board table ☢️

For years, guidelines have excluded the use of EBRT in the setting of HCC management, but 2024 was the year that kept on giving.

[Treating Cancer Dr Prinitha Pillay @TreatingC]

@StephDudzinski @NiuSanford Evidence of SBRT vs SIRT? Thanks

[International Society of Liquid Biopsy @isliquidbiopsy]

🧬 Liquid Biopsy in Clinical Practice: Past, Present & Future🩸

A new review explores the evolution, applications, and future directions of liquid biopsy in oncology. Here are the key insights:

🔬Technologies & Biomarkers

✅ Circulating Tumor Cells (CTCs) – Enrichment & detection methods (PCR, IHC, FISH, scRNA-seq)
✅ Circulating Tumor DNA (ctDNA) – PCR & NGS-based detection for genomic alterations
✅ Exosomes – Advanced methods for isolating tumor-derived extracellular vesicles

📊Clinical Applications

✅ Early Cancer Detection– Liquid biopsy enhances non-invasive screening
✅ Cancer Staging & Prognosis– Stratifies patients based on risk & molecular profiling
✅ Therapy Guidance – Detects actionable mutations like ESR1, PIK3CA, EGFR, ALK for precision medicine
✅ Treatment Response Monitoring – Tracks minimal residual disease (MRD) & therapy resistance

🚀Advancing Liquid Biopsy for Multi-Cancer Screening

✅ Emerging multi-cancer detection technologies: CCGA3, CancerSEEK, THUNDER, DETECT-A, PATHFINDER
✅ AI & machine learning integration for enhanced diagnostic accuracy

🔮Future Directions

✅ Standardization & Validation – Steps to clinical utility
✅ Multi-Omics Approach – Integrating genomics, transcriptomics, and proteomics
✅ Ex Vivo Models – Using CDX mouse models for precision therapy testing

🌍Liquid biopsy is revolutionizing oncology—enhancing early detection, personalized treatment & real-time monitoring.

🔗 Read the full study: https://t.co/NRKdWCiSah

@DrYukselUrun @ChristianRolfo @ElJanLe @UmbertoMalapel1 @oncodaily @ErulEnes @drgandara @MJOSESERRANO19 @CHematology @Elsevier_Med

#LiquidBiopsy #PrecisionOncology #ctDNA #CancerDetection #ISLB 🚀

[Neil Newman @nbn426]

Fantastic work by @StephDudzinski ! Honored to have partook . This is a must read for all docs taking care of liver patients on the rapidly changing role of RT given a multitude of clinical trials out in the last 1- 2 years! This EBM rendition of BCLC is how I try to operate @BCLC

https://t.co/7kPsZqW7y4

[Toni Choueiri, MD @DrChoueiri]

IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024

1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos
⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45)
⏩ OS benefit: 31.5 vs 16.1 mo (HR= 0.47)

@tompowles1 @NEJM #ESMO2023 Plenary

https://t.co/rv2QsoQf4J